Downloads   Careers   Contact     

Leading Brands

Brand building is at the core of our marketing strategy. A significant proportion of our revenues is derived from brands which are among top 10 in their respective subgroups. We derive a higher proportion of our revenues from our top 15 and top 25 mother brand groups, as compared to the average of the top 25 players in the IPM

  Top 15 Mother Brand Groups Revenue Contribution Top 25 Mother Brand Groups Revenue Contribution
Eris Lifesciences 78.1% 88.0%
Average of Top 25 Companies in IPM 50.5% 61.7%

Source: AIOCD MAT MARCH 2020

Top 15 Brands

Brand Year of launch Indication Subgroup(including combinations) Sales Value in INR Millions Brand CAGR (FY 15-20) Market CAGR (FY 15-20) Prescription rank
GLIMISAVE 2007 Anti – Diabetes Glimepiride 2,462 17% 14% 8
ERITEL 2008 Hypertension Telmisartan 1,373 12% 17% 8
RENERVE 2003 Neuropathy Methylcobalamin and combinations 1079 11% 8% 3
TENDIA 2015 Anti-Diabetes Teneligliptin 750 25.4% *  22% * 6
OLMIN 2010 Hypertension Olmesartan 670 15% 13% 6
CYBLEX 2014 Anti-Diabetes Gliclazide 634 81% 12% 7
LNBLOC 2012 Hypertension Cilnidipine 584 30% 31% 2
TAYO 2011 Vit. D deficiency in Metabolic disorders Vitamin D 557 5% 11% 7
REMYLIN 2007 Diabetic Neuropathy Mecobalamin+Colecalciferol 555 5% 10% 2
RABONIK 2008 Gastroenterology Rabeprazole 540 2% 9% 13
CREVAST 2010 Lipid Lowering Rosuvastatin 420 21% 22% 15
ATORSAVE 2007 Lipid Lowering Atorvastatin 356 2% 6% 13
ROSIFLEX 2013 Anti-Arthritic Rosa Canina extract 333 22% 54% 3
RARICAP 1990 Iron supplement Conventional Iron 274 13% 2% 3
GINKOCER Oct-92 Vertigo GINKGO BILOBA | V3B5 240 3% 3% 1

Source: AIOCD MAT Mar 2020
*Growth over FY 19 considered since brand launched post FY 15